MedTrace Logo

Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer

NCT06408623 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-05-10

No results posted yet for this study

Summary

The purpose of this study is to explore the safety and tolerability of chidamide in combination with Sintilimab and bevacizumab in patients with advanced liver cancer, to determine the recommended dose for this combination regimen, and to explore preliminary efficacy data. And based on the tumor immune microenvironment multidimensional (lymphocyte subsets, multiple cytokines, multicolor fluorescence immunohistochemistry, single cell sequencing, etc.) to explore the therapeutic efficacy related markers.

Conditions

Interventions

DRUG

chidamide combined with Sintilimab and bevacizumab

chidamide combined with Sintilimab and bevacizumab

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-15
Primary Completion
2025-05-15
Completion
2026-05-15

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06408623 on ClinicalTrials.gov